C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT ID: NCT07037277
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
880 participants
INTERVENTIONAL
2025-06-02
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
NCT05904470
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
NCT02722837
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
NCT02671500
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
NCT03074331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bemnifosbuvir - Ruzasvir (BEM/RZR)
Bemnifosbuvir-Ruzasvir
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
Sofosbuvir-Velpatasvir (SOF/VEL)
Sofosbuvir-Velpatasvir
SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bemnifosbuvir-Ruzasvir
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
Sofosbuvir-Velpatasvir
SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV)
* Documented medical history compatible with chronic HCV
* Either no liver cirrhosis or with compensated liver cirrhosis
* If HIV-1-positive, must meet the following 2 criteria:
1. Antiretroviral (ARV) regimen for \>8 weeks prior to screening visit, with CD4 T-cell count \>200 cells/mm3 and plasma HIV-1 RNA \<LLOQ
2. Suitable ARV treatment and not taking any contraindicated medications
Exclusion Criteria
* Co-infected with hepatitis B virus
* Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator
* Prior exposure to any HCV DAA
* Requirement of any prohibited medications
* Use of other investigational drugs within 30 days of dosing
* History or signs of decompensated liver disease (decompensated cirrhosis)
* History of hepatocellular carcinoma (HCC)
* Any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atea Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atea Study Site
Nice, Alpes Maritimes, France
Atea Study Site
Strasbourg, Bas Rhin, France
Atea Study Site
Clichy, Hauts de Seine, France
Atea Study Site
Montpellier, Herault, France
Atea Study Site
Clermont-Ferrand, Puy de Dome, France
Atea Study Site
Créteil, Val de Marne, France
Atea Study Site
Hamburg, Hamburg, Germany
Atea Study Site
Frankfurt am Main, Hesse, Germany
Atea Study Site
Leipzig, Saxony, Germany
Atea Study Site
Alexandroupoli, , Greece
Atea Study Site
Athens, , Greece
Atea Study Site
Athens, , Greece
Atea Study Site
Heraklion, , Greece
Atea Study Site
Hyderabad, Andhra Pradesh, India
Atea Study Site
Patna, Bihar, India
Atea Study Site
Rajkot, Gujarat, India
Atea Study Site
Surat, Gujarat, India
Atea Study Site
Shimla, Himachal Pradesh, India
Atea Study Site
Belagavi, Karnataka, India
Atea Study Site
Kochi, Kerala, India
Atea Study Site
Mumbai, Maharashtra, India
Atea Study Site
Nagpur, Maharashtra, India
Atea Study Site
Pune, Maharashtra, India
Atea Study Site
Pune, Maharashtra, India
Atea Study Site
Ludhiana, Punjab, India
Atea Study Site
Agra, Uttar Pradesh, India
Atea Study Site
Kanpur, Uttar Pradesh, India
Atea Study Site
Lucknow, Uttar Pradesh, India
Atea Study Site
Varanasi, Uttar Pradesh, India
Atea Study Site
Kolkata, West Bengal, India
Atea Study Site
Kota Bharu, Kelantan, Malaysia
Atea Study Site
Kota Bharu, Kelantan, Malaysia
Atea Study Site
Ampang, Kuala Lumpur, Malaysia
Atea Study Site
Kuala Lumpur, Kuala Lumpur, Malaysia
Atea Study Site
Kuantan, Pahang, Malaysia
Atea Study Site
Kota Kinabalu, Sabah, Malaysia
Atea Clinical Study Site
Chisinau, , Moldova
Atea Study Site
Islamabad, , Pakistan
Atea Study Site
Islamabad, , Pakistan
Atea Study Site
Karachi, , Pakistan
Atea Study Site
Karachi, , Pakistan
Atea Study Site
Karachi, , Pakistan
Atea Study Site
Karachi, , Pakistan
Atea Study Site
Lahore, , Pakistan
Atea Study Site
Lahore, , Pakistan
Atea Study Site
Lahore, , Pakistan
Atea Study Site
Peshawar, , Pakistan
Atea Study Site
Rawalpindi, , Pakistan
Atea Study Site
Krakow, , Poland
Atea Study Site
Kłodzko, , Poland
Atea Study Site
Lublin, , Poland
Atea Study Site
Mysłowice, , Poland
Atea Study Site
Warsaw, , Poland
Atea Study Site
Wroclaw, , Poland
Atea Study Site
Bucharest, , Romania
Atea Study Site
Bucharest, , Romania
Atea Study Site
Bucharest, , Romania
Atea Study Site
Bucharest, , Romania
Atea Study Site
Constanța, , Romania
Atea Study Site
Craiova, , Romania
Atea Study Site
Galati, , Romania
Atea Study Site
Iași, , Romania
Atea Study Site
Sibiu, , Romania
Atea Study Site
Suceava, , Romania
Atea Study Site
Port Elizabeth, Eastern Cape, South Africa
Atea Study Site
Bloemfontein, Free State, South Africa
Atea Study Site
Johannesburg, Gauteng, South Africa
Atea Study Site
Johannesburg, Gauteng, South Africa
Atea Study Site
Johannesburg, Gauteng, South Africa
Atea Study Site
Pretoria, Gauteng, South Africa
Atea Study Site
Brits, North West, South Africa
Atea Study Site
Somerset West, Western Cape, South Africa
Atea Study Site
Seoul, Gyeonggi-do, South Korea
Atea Study Site
Yangsan, Gyeongsangnam-do, South Korea
Atea Study Site
Busan, , South Korea
Atea Study Site
Busan, , South Korea
Atea Study Site
Seoul, , South Korea
Atea Study Site
Barcelona, Barcelona, Spain
Atea Study Site
Santander, Cantabria, Spain
Atea Study Site
Málaga, Malaga, Spain
Atea Study Site
Vigo, Pontevedra, Spain
Atea Study Site
Bangkok, Bangkok, Thailand
Atea Study Site
Pathum Wan, Bangkok, Thailand
Atea Study Site
Ratchathewi, Bangkok, Thailand
Atea Study Site
Mueang Nonthaburi, Changwat Khon Kaen, Thailand
Atea Study Site
Hat Yai, Changwat Songkhla, Thailand
Atea Study Site
Mueang Nonthaburi, Chiang Mai, Thailand
Atea Study Site
Ankara, , Turkey (Türkiye)
Atea Study Site
Denizli, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AT-01B-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.